Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea

Esther Rey1†, Elvira del Pozo-Maroto1†, Patricia Marañoñ1†, Brittany Beeler1, Yaiza García-García1, Pedro Landete2, Stephania C. Isaza1, Ramón Farré3, Carmelo García-Monzón1*, Isaac Almendros3‡ and Águeda González-Rodríguez1‡

1 Research Unit, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, CIBERehd, Madrid, Spain, 2 Respiratory Medicine Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa Hospital Universitario de La Princesa, Madrid, Spain, 3 Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, CIBERES, IDIBAPS, Barcelona, Spain

Nocturnal intermittent hypoxia (IH) featuring obstructive sleep apnea (OSA) dysregulates hepatic lipid metabolism and might contribute to the development of non-alcoholic fatty liver disease (NAFLD) observed in OSA patients. However, further research is required to better understanding the molecular mechanisms underlying IH-induced hepatic lipid accumulation. Therefore, the aim of the present study was to determine the effects of OSA on hepatic CD36 expression and the impact of IH by using a mouse model of OSA. Histological analysis, lipid content and CD36 expression were assessed in livers from subjects who underwent liver biopsy and polygraphic study during sleep, and in livers from mice submitted to chronic IH mimicking OSA. Among those who presented OSA features, NAFLD were significantly more frequent than in control subjects with normal respiratory function (77.8 vs. 36.4%, respectively), and showed more severe liver disease. Interestingly, CD36 expression was significantly overexpressed within the liver of OSA patients with respect to controls, and a significant positive correlation was observed between hepatic levels of CD36 and the values of two well-known respiratory parameters that characterized OSA: apnea/hypopnea index (AHI) and oxygen desaturation index (ODI). Moreover, hepatic lipid accumulation as well as induction of hepatic lipogenic genes, and CD36 mRNA and protein expression were significantly higher in livers from mice exposed to IH conditions for 8 weeks than in their corresponding littermates. This study provides novel evidence that IH featuring OSA could contribute to NAFLD setup partly by upregulating hepatic CD36 expression.

Keywords: obstructive sleep apnea, intermittent hypoxia, CD36, steatosis, NAFLD

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is characterized by metabolic dysfunction and accumulation of lipid deposits in the livers of patients in whom alcohol abuse is not the causal agent of disease onset (1). NAFLD encompasses a wide range of histologic findings from simple steatosis to non-alcoholic steatohepatitis (NASH) with fibrosis and, ultimately, liver cirrhosis, and hepatocellular carcinoma (2). The number of individuals affected by some clinical form of this chronic liver disease is steadily increasing because NAFLD is highly associated with obesity and type 2 diabetes, being considered the hepatic manifestation of the metabolic syndrome (3).
It is well-known that the liver maintains bodily lipid homeostasis by regulating hepatic free fatty acid (FFA) uptake, lipid synthesis, lipid oxidation, and lipid export; however, an imbalance between these metabolic pathways can lead to an excessive lipid accumulation within the liver (4), being an increased de novo lipogenesis and largely an enhanced uptake of FFAs released from insulin resistant-adipocytes the main sources of these lipid accumulates (5). The uptake of FFAs into hepatocytes is mainly dependent on the fatty acid translocase CD36 which, under physiological conditions, is weakly expressed in the liver and its expression increases by a number of different stimuli, such as insulin and lipid metabolites, facilitating the process of FFA uptake (6). Some experimental studies have demonstrated that CD36 plays an important role in NAFLD setup in rodents (7, 8) and, reinforcing this notion, it has been observed that fatty liver attenuates in mice fed high fat diet (HFD) upon either systemic or hepatocyte-specific deletion of CD36 (9, 10). Moreover, a growing clinical evidence suggests that this FFA transporter could play a relevant role in NAFLD pathogenesis in humans as well. In particular, Greco et al. showed that hepatic CD36 mRNA levels correlated with liver fat content in morbidly obese patients (11). In addition, different clinical studies have convincingly shown that the amount of both CD36 mRNA and protein was higher in the livers of biopsy-proven NAFLD patients than in subjects with histologically normal liver (12–14).

An increasing number of clinical studies point out to a potential link between obstructive sleep apnea (OSA), a respiratory disorder featured by nocturnal intermittent hypoxia (IH) and sleep fragmentation, and NAFLD (15–18). To highlight, both OSA and NAFLD are especially prevalent among obese individuals and, more interestingly, the severity of nocturnal IH positively correlates with histological features of NASH in OSA patients (19). Although the underlying molecular mechanisms are not fully understood, it has been reported that IH exacerbated fatty liver in obese mice by inducing hepatic lipid biosynthesis (20) likely due to the upregulation of the HIF1α/SREBP1c signaling pathway (21), and that promoted liver inflammation and fibrosis in mice fed with a HFD (22). However, further research is required to unveil the pathophysiological interplays between IH and lipid accumulation. In that regard, whether IH is able to regulate CD36 gene expression in hepatocytes still remains to be elucidated.

Therefore, the primary objective of this study was to determine the impact of IH on CD36 expression as well as on lipid content in livers from OSA patients with biopsy-proven NAFLD and in livers from mice exposed to IH.

**MATERIALS AND METHODS**

**Patients**

This study was performed in agreement with the Declaration of Helsinki, and with local and national laws. The Human Ethics Committee of the Hospital Universitario Santa Cristina (HUSC, Madrid, Spain) approved all procedures (PI-688A). This cross-sectional study included 20 patients with gallstones to whom a programmed laparoscopic cholecystectomy was performed in the HUSC. All participants gave a written consent for a perioperative liver biopsy and a postoperative respiratory polygraphy as part of an experimental protocol designed to evaluate the relationship between sleep disturbances and liver disease. All subjects included drank <20 g/day of alcohol, had no previous respiratory disorders, were not having potentially hepatotoxic drugs, had no analytical evidence of iron overload, and were seronegative for autoantibodies, for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus.

**Sleep Study**

The polygraphic studies were performed at night in the Sleep Laboratory of the HUSC (Madrid, Spain). For interpretation, the recommendations of the American Academy of Sleep Medicine (AASM) for the diagnosis of OSA were followed. The apnea/hypopnea index (AHI) was used as diagnostic criteria for severity of OSA: AHI < 5, no OSA; AHI 5–14, mild OSA; AHI 15–29, moderate OSA; AHI ≥30, severe OSA. In addition, nocturnal hypoxemia parameters including oxygen desaturation index (ODI), cumulative sleep time percentage with oxyhemoglobin saturation (SpO2) < 90% (Tc90) and minimum SpO2 were analyzed.

**Animal Care and Intermittent Hypoxia Protocol**

Twelve-weeks-old C57BL/6j mice were purchased from Charles River Laboratories (Saint Germain sur L’Arbresle, France) and divided into two groups of 10 mice. The control mice (C mice) were placed in conditions of normoxia while the experimental group (IH mice) was subjected to IH conditions. Every minute, IH mice received air containing an oxygen fraction of 5% for 20 s, followed by 40 s of room air, during 6 h per day, 5 days a week for a total of 8 weeks. Control mice were only exposed to room air (23). At the end of the experiment, mice were anesthetized, sacrificed and livers were harvested. All experimental procedures were approved by the Ethical Committee of the University of Barcelona (174/18–10268).

**Histopathology Assessment**

Liver sections (5 μm) were embedded in paraffin and cut using a Microm microtome (Midland, ON, Canada). After cutting, sections were stained with hematoxylin (1.09235.0500, PanReac AppliChem, Barcelona, Spain) and eosin (71211, Thermo Fisher Scientific, Inc., Madrid, Spain) and with Masson’s Trichrome Solution (Masson Trichrome Kit with Aniline Blue 04-010802, Milan, Italy). Once stained, the severity of steatosis was quantified by a single-blind hepatopathologist. Specifically, Kleiner’s histological scoring system was employed to evaluate the degree of steatosis, lobular inflammation, hepatocellular ballooning, and the stage of fibrosis (24). The following percentages of steatotic hepatocytes were used in the histological assessment: 0–5% hepatocytes, grade 0; 5–33%, grade 1; 33–66%, grade 2; and >66%, grade 3. Histologic diagnosis of liver biopsies was classified into two groups: simple steatosis without hepatocellular ballooning nor lobular inflammation, also termed NAFL, and NASH. Minimal criteria for NASH included the combined presence of grade 1 steatosis, lobular inflammation and hepatocellular ballooning with or without fibrosis. NAFLD
activity score was also calculated for each liver biopsy (24). To this end, three different lobular areas were analyzed in each sample. Representative images were taken using a Nikon Eclipse E400 optical microscope (Nikon, Tokyo, Japan) and the NIS Elements Imaging Software (Melville, NY, USA).

**Assessment of Lipid Accumulation**
Liver tissue was embedded in Tissue-Tek® O.C.T.™ Compound (Sakura Finetek Europe, Netherlands). Sections (10 µm) were then cut using a Leica CM1510S cryostat (Leica Microsystems S.L.U, Barcelona, Spain), stained using an Oil Red O biological stain (Sigma-Aldrich, St. Louis, MO, USA) working solution (60% ORO/isopropanol w:v), and counterstained with hematoxylin (1.09235.0500, PanReac AppliChem). Three different lobular areas were analyzed in each sample and photographed using a Nikon Eclipse E400 optical microscope (Nikon) and the NIS Elements Imaging Software (Melville). Intensity of red stain was quantified using ImageJ Biological Image Analysis (NIH) and reported as the average value in arbitrary units (a.u.).

**Quantitative Analysis of Hepatic Triglycerides**
Triglycerides (TGs) were extracted as described previously (25). Briefly, liver biopsy samples (15–20 µg) were homogenized in distilled water. Chloroform (−20°C) and methanol (−20°C) were added to each sample. Samples were centrifuged and the triglyceride-containing layer was collected. Once purified, TGs were suspended in isopropanol and analyzed using a colorimetric kit (SpinReact, Girona, Spain). Absorbance values were obtained using a Dynex Spectra MR Microplate spectrophotometer/computer software (Chantilly, VA, USA) and graphically expressed as mg/dl.

**Protein Extraction and Western Blot Analysis**
Liver biopsy samples (15–20 µg) were homogenized in an extraction buffer containing the following: 10 mM ethylene-diamine-tetraacetic acid (EDTA), 50 mM Hepes, 50 mM sodium pyrophosphate, 0.1 mM NaF, 10 mM Na3VO4, 1% Triton X-100 and protease inhibitors. Protein extracts were stored at −80°C after centrifugation. A small aliquot of sample was used for protein quantification (Bradford method). The samples were then prepared to be loaded into 8% SDS-PAGE gels. After running, proteins were further transferred to Immunoblot nitrocellulose membranes (BioRad Inc., Madrid, Spain), blocked with 5% non-fat dry milk and incubated overnight with primary antibodies: CD36/SR-B3 (1:1000, NB400-144, Novus Biotechnic, Abingdon, United Kingdom) and anti-β-actin (1:5000, A-5441, Sigma Aldrich). Then, the corresponding secondary antibodies were added (Santa Cruz Biotechnology Inc., Heidelberg, Germany). Using the Bio-Rad Clarity™ Western ECL Substrate (BioRad Inc.), the immunoreactive bands were visualized by the ImageQuant LASD 4000 digital imaging system (GE Healthcare Europe, Barcelona, Spain). Densitometric analysis of the band was performed using ImageJ Biological Image Analysis (NIH), normalized against the loading control (β-actin), and graphically expressed as fold change relative to control condition (1).

**Statistical Analysis**
Categorical variables were presented as percentage and were compared by the Pearson χ² test. Continuous data were shown as standard deviation (SD) or standard error of mean (SEM), and were compared using the unpaired t-test or Mann-Whitney U-test, as indicated. The Spearman’s r-test was used to evaluate correlations. All statistical analyses were performed using the GraphPad Prism 6 software (GraphPad Software Inc., San Diego, CA, USA) and SPSS statistical software version 24.0 (IBM SPSS Statistics, Armonk, NY), with a p < 0.05 considered statistically significant.

**RESULTS**

**Characteristics of the Study Patients**
Twenty patients undergoing programmed cholecystectomy had both a liver biopsy and a sleep study. Overall, the mean age of the study population was 46.5 years, 14 (70%) were female and 9 (45%) had a diagnosis of OSA by polygraphy (AHI > 5). Patient characteristics from the cohort included in this study are presented in Table 1.
TABLE 1 | Demographic, metabolic, biochemical, respiratory, and histological characteristics of the study population.

| Feature                   | Patients without OSA ($n = 11$) | Patients with OSA ($n = 9$) | p-value |
|---------------------------|----------------------------------|-------------------------------|---------|
| Age (years)               | 39.9 ± 9.6                       | 54.6 ± 10.6                   | 0.004   |
| BMI (kg/m$^2$)            | 26.5 ± 6.7                       | 28.6 ± 5.1                    | 0.201   |
| Waist circumference (cm)  | 91.8 ± 14.4                      | 105.5 ± 11.6                  | 0.034   |
| Glucose (mg/dL)           | 92.2 ± 9.3                       | 96.2 ± 11.9                   | 0.359   |
| Insulin ($\mu$U/L)        | 7.2 ± 2.9                        | 9.2 ± 4.5                     | 0.245   |
| HOMA-IR                   | 1.6 ± 0.7                        | 2.1 ± 1                       | 0.192   |
| Triglycerides (mg/dL)     | 111.2 ± 54.2                     | 136.4 ± 68.9                  | 0.467   |
| Total Cholesterol (mg/dL) | 207 ± 132.3                      | 210 ± 29.5                    | 0.832   |
| HDL-cholesterol (mg/dL)   | 53.5 ± 12.8                      | 46.9 ± 9.5                    | 0.212   |
| ALT (IU/L)                | 24.6 ± 17.4                      | 27.2 ± 19.3                   | 0.469   |
| AST (IU/L)                | 22.1 ± 9.3                       | 21.3 ± 5.6                    | 0.808   |
| γGT (IU/L)                | 33.4 ± 24.4                      | 28.4 ± 14.5                   | 0.601   |
| Alkaline phosphatase (IU/L)| 70.3 ± 22.7                     | 61 ± 13.6                     | 0.359   |
| Bilirubin (mg/dL)         | 0.7 ± 0.36                       | 0.63 ± 0.32                   | 0.780   |
| Average oxygen saturation (%) | 94.7 ± 1.7          | 93.3 ± 1.4                    | 0.225   |
| Minimum oxygen saturation (%) | 88.2 ± 4.2                  | 83.7 ± 5.9                    | 0.073   |
| AHI (events/hour)         | 0.9 ± 1                           | 10.9 ± 9.2                    | 0.002   |
| ODI (events/hour)         | 0.64 ± 0.6                       | 9.2 ± 9.5                     | <0.001  |
| Tc90 (%)                  | 7.5 ± 16.9                       | 6 ± 8.8                       | 0.053   |

NAS Score (%)

|          |        |
|----------|--------|
| 0        | 22.2%  |
| 1        | 22.2%  |
| 2        | 22.2%  |
| 3        | 11.2%  |
| 4        | 22.2%  |

Steatosis (%)

|        |        |
|--------|--------|
| Grade 0 | 63.6%  |
| Grade 1 | 27.3%  |
| Grade 2 | 9.1%   |
| Grade 3 | 11.1%  |

Lobular Inflammation (%)

|        |        |
|--------|--------|
| Grade 0 | 91%    |
| Grade 1 | 9%     |
| Grade 2 |        |

Ballooning (%)

|        |        |
|--------|--------|
| Grade 0 | 100%   |
| Grade 1 | 77.8%  |
| Grade 2 | 22.2%  |

Fibrosis (%)

|        |        |
|--------|--------|
| Stage 0 | 100%   |

OSA patients were significantly older than those without OSA (p = 0.004) and women predominated in both groups. In order to evaluate the presence of obesity in the entire study population, body mass index (BMI) was calculated and waist circumference was measured in each participant. Regarding BMI, the study population showed an overweight status and no significant differences were found among the different patient groups studied (p = 0.201), whereas waist perimeter was significantly higher in patients with OSA than in those without (p = 0.034).

As expected, OSA patients had a significantly higher rate of oxygen desaturation per hour of sleep (ODI) and percentage of sleep time with oxygen saturations lower than 90% (Tc90) with respect to patients without OSA (Table 1).

Regarding metabolic parameters, basal glucose levels did not significantly differ between groups, while insulin levels and the degree of insulin resistance assessed by HOMA-IR index were higher in OSA patients than in those without OSA, but these differences were not statistically significant (Table 1).

Although no significant differences were observed in liver enzymes between the two groups, there was a higher prevalence of NAFLD and evidence of more severe disease among patients with OSA (Table 1 and Figure 1A). Surprisingly, 36.4% of patients without OSA exhibited NAFLD, all of them featuring simple steatosis. In the OSA group, however, 55.6% of them had simple steatosis and 22.2% showed histological features of steatohepatitis (NASH) (Table 1 and Figure 1A). Hepatic fibrosis was not observed. All other variables did not significantly differ between groups.

Expression of CD36 Is Increased Within the Liver of OSA Patients

Next, we wanted to investigate whether OSA might alter CD36 expression in the liver. Interestingly, hepatic mRNA levels of CD36 were significantly higher in patients with OSA when compared with control patients (Figure 1B), and its expression significantly positively correlated with both AHI and ODI values in the entire study population (Figure 1C), but not with Tc90 (Supplementary Figure 1A). In parallel, an increase of CD36 protein expression was also observed in the livers from OSA patients compared with those from the control group detected by immunostaining (Figure 1D).

Intermittent Hypoxia (IH) Triggers Hepatic Steatosis in Mice

In order to investigate whether intermittent hypoxia (IH), one of the main features of OSA, contributes to liver steatosis and to the increase of CD36 expression observed in OSA patients, a mouse experimental model of OSA was used. After 2 months of IH exposure, histological examinations of liver tissue revealed that 60% of the mice submitted to IH exhibited signs of mild hepatic steatosis while control mice displayed normal liver features (Figures 2A,B). Liver fibrosis was not detected in any of the groups (Supplementary Figure 2).

Next, we investigated the amount of lipids performing an Oil Red O staining on sections of liver biopsy samples from...
all mice. The results indicated that there was a significant increase in average red-stain intensity (directly proportional to lipid content) among the IH mice when compared to control mice (Figure 2C). To further evaluate hepatic lipid content, triglycerides were extracted and quantified from liver biopsies of both IH and C mice. Triglyceride levels of the IH mice were greater than those observed in the C mice (Figure 2D).
FIGURE 2 | Intermittent Hypoxia (IH) is associated with increased hepatic lipid content in mice. (A) Representative 20X and 60X images of liver sections stained with hematoxylin and eosin (H&E). Scale bar 100 and 50 µm, respectively. (B) NAFLD activity score. (C) (left panel) Representative 40X and 60X images of Oil Red O stained liver sections. Scale bar 50 µm. (right panel) Quantification of red-stain intensity. (D) Analysis of hepatic triglyceride (TG) levels. Experimental groups: mice maintained in normoxic conditions (Control, C) and mice exposed to intermittent hypoxia (IH) (n = 10 mice in each group). **p < 0.01 and ***p < 0.005, IH vs. C, compared using the unpaired t-test.
Intermittent Hypoxia Induces Hepatic CD36 Expression in Mice

**A** mRNAs levels of *Fasn, Scd1, Cpt1a*, and *Ppara*. **(B)** Cd36 mRNA levels. **(C)** (left panel) Representative blots with the indicated antibodies. (right panel) Quantification of all blots with respect to loading control, *β*-actin. **(D)** (left panel) Representative 20X and 60X images from CD36 immunohistochemistry. Scale bar 100 and 50 µm, respectively. (right panel) Quantification of CD36-stain intensity. Experimental groups: mice maintained in normoxic conditions (Control, C) and mice exposed to intermittent hypoxia (IH) (*n* = 10 mice in each group). *p* < 0.05 and ***p* < 0.005, IH vs. C, compared using the unpaired *t*-test.
**Intermittent Hypoxia (IH) Induces Hepatic CD36 Expression**

Then, we analyzed the hepatic expression of genes involved in the regulation of lipid metabolism. We observed a significant increase in the expression of genes implicated in lipid synthesis, such as *Fasn* (fatty acid synthase) and *Scd1* (stearoyl-CoA desaturase 1), among livers from mice exposed to IH (Figure 3A); however, no differences were observed in the expression of genes implicated in β-oxidation, such as *Cpt1a* (carnitine palmitoyltransferase 1) and *Ppara* (peroxisome proliferator activated receptor alpha) (Figure 3A).

With respect to CD36, its hepatic mRNA expression was significantly increased in mice submitted to IH compared to those maintained in normoxic conditions (Figure 3B), which was also found in OSA patients. In parallel, its protein expression determined by both Western blot (Figure 3C) and immunohistochemistry (Figure 3D) was elevated in the livers of IH mice.

**DISCUSSION**

Distinct clinical studies have reported that OSA is significantly associated with NAFLD severity (26) and there is an increasing experimental evidence that chronic IH, the best characterized OSA manifestation, is a major trigger for oxidative stress and inflammatory liver injury leading to NAFLD progression (17). In agreement with these previous studies, we found that 22.2% of OSA patients had NASH whereas none of those without OSA had histological features of NASH, supporting the assumption that OSA is a risk factor for progression from simple steatosis to NASH (27). Interestingly, our findings showed that there were no differences regarding BMI between the two study groups, but waist circumference was significantly higher in patients with OSA, suggesting that is abdominal obesity, but not overall obesity, what actually has a clinical impact on the features of metabolic syndrome, including OSA and NAFLD.

To the best of our knowledge, this is the first study revealing that CD36 expression is significantly elevated in livers from patients with OSA. Moreover, both AHI and ODI positively correlated with hepatic CD36 mRNA levels, indicating a potential role for nocturnal IH in the upregulation of this FFA transporter. An intriguing question regarding our findings showed herein is whether age might influence the hepatic CD36 expression pattern observed in OSA patients because they were significantly older (54.6 ± 10.6 years) than those without OSA (39.9 ± 9.6 years). Indeed, we have reported that hepatic CD36 expression increased with aging in mice and humans (13), but the age-dependent increases in hepatic CD36 expression were observed comparing young (20–38 years old) with aged individuals (50–83 years), thus we believe that age differences seen in our study population are not sufficient to explain the hepatic CD36 upregulation observed in OSA patients. Supporting this assumption, no correlation was found between CD36 mRNA expression and age in our study population (Supplementary Figure 1B).

In agreement with our findings in OSA patients, the majority of mice exposed to IH displayed simple steatosis as well as a higher hepatic TG content and CD36 expression than in control mice breathing normal oxygen concentrations. Collectively, our results indicate that IH may contribute to hepatosteatosis setup, partly by the upregulation of hepatic CD36 expression, but the underlying molecular mechanisms still remain to be elucidated.

It is well-known that cellular adaptive responses to hypoxia are tightly regulated by hypoxia-inducible transcription factors (HIFs), being HIF1α and HIF2α the best characterized (28). In that regard, Li et al. demonstrated that IH exacerbated hepatosteatosis in mice in parallel with an upregulation of key genes for hepatic lipid biosynthesis, such as *Srebp1* and *Scd1* (20) and that this effect is mediated through HIF1α (29). In line with these results, our study also found increased mRNA levels of relevant genes for *de novo* lipogenesis, such as *Fasn* and *Scd1*, along with an upregulation of CD36 gene expression in livers of mice exposed to IH, suggesting that HIF1α might regulate CD36 gene expression as well. There is convincing evidence, however, indicating that the regulation of CD36 expression is not largely linked to the HIF1α/SREBP1c signaling pathway in hepatocytes. Notably, it has been recently reported that hepatocyte-specific *Srebp1* downregulation did not affect expression of genes involved in FFA uptake as CD36 in mouse livers (30). In addition, we have just demonstrated that both CD36 expression and triglyceride content increased in mouse and human liver cells under hypoxic conditions and that silencing *HIF2A* gene markedly suppressed both CD36 gene upregulation and lipid accumulation in hepatocytes (14). The novelty of our present study is that both CD36 expression and the degree of steatosis are increased in livers from animal models of IH and in patients with OSA featured by nocturnal IH, supporting the notion that CD36 could be a key factor driving hepatosteatosis in OSA patients.

In conclusion, the results of the present study demonstrate that CD36 expression is increased within the liver of patients with OSA and in mice exposed to IH, the clinical hallmark featuring OSA. Moreover, our results point out that the excessive lipid accumulation observed in livers of mice under IH conditions is likely due to the upregulation of CD36, which is involved in FFA uptake into hepatocytes, along with that of genes implicated in *de novo* lipogenesis, thus leading to the onset of hepatosteatosis, the earliest phase of NAFLD. Collectively, our findings shed light on the molecular mechanisms underlying IH-induced hepatosteatosis helping to understand better the NAFLD pathogenesis and identifying CD36 as a potential target for new pharmacological therapies to NAFLD patients.

**DATA AVAILABILITY STATEMENT**

All datasets presented in this study are included in the article/Supplementary Material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Human Ethics Committee of the Hospital Universitario Santa Cristina. The patients/participants provided
their written informed consent to participate in this study. The animal study was reviewed and approved by Ethical Committee of the University of Barcelona.

AUTHOR CONTRIBUTIONS
CG-M, IA, and ÁG-R designed the study. EP-M, PL, and CG-M carried out and analyzed the clinical study. ER, BB, PM, and SI carried out the experimental study. RF, CG-M, IA, and ÁG-R analyzed and discussed data. IA and ÁG-R wrote the manuscript. All authors were involved in editing the paper and had final approval of the submitted and published versions.

FUNDING
This work was supported by P113/01299, P117/00535 and CIBEREHD from Instituto de Salud Carlos III (ISCIII/FEDER, Spain) to CG-M; P116/00823 and P119/00123 (ISCIII/FEDER, Spain), and Beca Eduardo Gallego 2016 (Fundación Francisco Cobos, Spain) to ÁG-R. RF was supported by the Spanish Ministry of Science, Innovation and Universities (SAF2017-85574-R) and CIBERES.

ACKNOWLEDGMENTS
We thankfully acknowledge Esther Fuertes Yebra for helpful technical assistance.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.00450/full#supplementary-material

Supplementary Table 1 | Primer sequences for RT-qPCR.
Supplementary Figure 1 | Correlation in the study population of matched mRNA values for CD36 with Tc90 values (A) and age (B), evaluated by Spearman’s r-test. Study population: control group (No-CSA) (n = 11) and CSA patients (n = 9).
Supplementary Figure 2 | Representative images of liver sections stained with Masson’s trichrome solution. Experimental groups: mice raised in normoxic conditions (Control, C) and mice exposed to intermittent hypoxia (IH) (n = 10 mice in each group).

REFERENCES
1. Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. (2017) 9:715–32. doi: 10.4254/wjh.v9.i16.715
2. Perumal BI, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of non-alcoholic fatty liver disease. World J Gastroenterol. (2017) 23:8263–76. doi: 10.3748/wjg.v23.i47.8263
3. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. (2020) 69:364–8. doi: 10.1136/gutjnl-2019-318813
4. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of non-alcoholic steatohepatitis: the central role of non-triglyceride fatty acid metabolites. Hepatology. (2010) 52:774–88. doi: 10.1002/hep.23719
5. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. (2013) 48:434–41. doi: 10.1007/s00535-013-0758-5
6. Bonen A, Chabowski A, Luiken JJ, Glatz JF. Is membrane transport of FFA mediated by lipid, protein, or both? Mechanisms and regulation of protein-mediated cellular fatty acid uptake: molecular, biochemical, and physiological evidence. Physiology. (2007) 22:15–29. doi: 10.1152/physiolonline.2007.22.1.15
7. Koenen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. (2007) 56:2863–71. doi: 10.2337/db07-0907
8. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. (2008) 134:556–67. doi: 10.1053/j.gastro.2007.11.037
9. Hajri T, Han XX, Bonen A, Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in Cd36-null mice. J Clin Invest. (2002) 109:1381–9. doi: 10.1172/JCI021456
10. Wilson CG, Tran JL, Eron DM, Vera NR, Febbraio M, Weiss EJ. Hepatocyte-specific disruption of Cd36 attenuates fatty liver and improves insulin sensitivity in HFD-Fed mice. Endocrinology. (2016) 157:570–85. doi: 10.1210/endo.2015-1866
11. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. (2008) 294:G1281–7. doi: 10.1152/ajpgi.00074.2008
12. Miquela-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Medivilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. (2011) 60:1394–402. doi: 10.1136/gut.2010.222844
13. Sheedfar F, Sung MM, Aparicio-Vergara M, Kloosterhuis NJ, Miquela-Colina ME, Vargas-Castrillon J, et al. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to non-alcoholic fatty liver disease. Aging. (2014) 6:281–95. doi: 10.18632/aging.100652
14. Rey E, Melendez-Rodriguez F, Maranon P, Gil-Valle M, Carrasco AG, Torres-Capelli M, et al. Hypoxia-inducible factor 2alpha drives hepatosteatosis through the fatty acid translocase CD36. Liver Int. (2020) 54:472–483. doi: 10.1111/liv.14519
15. Frohnhofen H, Roffe C. Intermittent nocturnal hypoxemia in individuals with dementia: prevalence and relationship with functional status. J Am Geriatr Soc. (2012) 60:1997–9. doi: 10.1111/j.1532-5415.2012.04183.x
16. Sforza E, Roche F. Chronic intermittent hypoxia and obstructive sleep apnea: an experimental and clinical approach. Hypoxia. (2016) 4:99–108. doi: 10.2147/HP.S103091
17. Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath. (2018) 22:841–51. doi: 10.1007/s11325-018-1625-7
18. Schwenger KJ, Ghorbani Y, Li C, Fischer SE, Jackson TD, Okrainec A, et al. Obstructive sleep apnea and non-alcoholic fatty liver disease in obese patients undergoing bariatric surgery. Obes Surg. (2020) 30:2572–8. doi: 10.1007/s11695-020-04514-3
19. Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and non-alcoholic fatty liver disease. Am J Respir Crit Care Med. (2019) 199:830–41. doi: 10.1164/rcrm.201806-1109TR
20. Li J, Grigoryev DN, Ye SQ, Thorne L, Schwartz AR, Smith PL, et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol. (2005) 99:1643–8. doi: 10.1152/japplphysiol.00522.2005
21. Li J, Nanayakkara A, Jun J, Savransky V, Polotsky VY. Effect of deficiency in SREBP cleavage-activating protein on lipid metabolism during intermittent hypoxia. Physiol Genom. (2007) 31:273–80. doi: 10.1152/physiogenomics.00082.2007
22. Kang HH, Kim IK, Lee HJ, Joo H, Lim JU, Lee J, et al. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity.
via TLR4/MyD88/MAPK/NF-kB signaling pathways. *Biochem Biophys Res Commun.* (2017) 490:349–55. doi: 10.1016/j.bbrc.2017.06.047

23. Almendros I, Montserrat JM, Torres M, Bonasignore MR, Chimenti L, Navajas D, et al. Obesity and intermittent hypoxia increase tumor growth in a mouse model of sleep apnea. *Sleep Med.* (2012) 13:1254–60. doi: 10.1016/j.sleep.2012.08.012

24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. *Hepatology.* (2005) 41:1313–21. doi: 10.1002/hep.20701

25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol.* (1959) 37:911–7. doi: 10.1139/y59-099

26. Parikh MP, Gupta NM, Mccullough AJ. Obstructive sleep apnea and the liver. *Clin Liver Dis.* (2019) 23:363–82. doi: 10.1016/j.cld.2019.01.001

27. Aron-Wisnewsky J, Minville C, Tordjman J, Levy P, Bouillot JL, Basdevant A, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. *J Hepatol.* (2012) 56:225–33. doi: 10.1016/j.jhep.2011.04.022

28. Semenza GL. Hypoxia-inducible factors in physiology and medicine. *Cell.* (2012) 148:399–408. doi: 10.1016/j.cell.2012.01.021

29. Li J, Bosch-Marce M, Nanayakkara A, Savransky V, Fried SK, Semenza GL, et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. *Physiol Genom.* (2006) 25:450–7. doi: 10.1152/physiolgenomics.00293.2005

30. Liu Y, Lin H, Jiang L, Shang Q, Yin L, Lin JD, et al. Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes. *J Clin Invest.* (2020) 130:2992–3004. doi: 10.1172/JCI128073

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Rey, del Pozo-Maroto, Marañón, Beeler, García-García, Landete, Isaza, Farré, García-Monzón, Almendros and González-Rodríguez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.